A child with resistant Kawasaki disease successfully treated with anakinra: a case report
| Autor: | Judith Sánchez-Manubens, Josefa Rivera, N. Franch, S. Teodoro, A. Gelman, N. Rudi, J. R. Palacios, Jordi Anton |
|---|---|
| Přispěvatelé: | Universitat de Barcelona |
| Rok vydání: | 2016 |
| Předmět: |
Vasculitis
Pediatrics medicine.medical_specialty Anti-Inflammatory Agents Infants malalts Case Report Mucocutaneous Lymph Node Syndrome 03 medical and health sciences 0302 clinical medicine Coronary Aneurysms Second line Refractory 030225 pediatrics hemic and lymphatic diseases IVIG resistance Medicine Humans Pediatrics Perinatology and Child Health 030203 arthritis & rheumatology Kawasaki disease Anakinra IL1 blockade biology business.industry lcsh:RJ1-570 lcsh:Pediatrics Sick children medicine.disease Case report Surgery Interleukin 1 Receptor Antagonist Protein Child Preschool Pediatrics Perinatology and Child Health Etiology biology.protein Female Antibody business Systemic vasculitis medicine.drug |
| Zdroj: | BMC Pediatrics BMC PEDIATRICS r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu instname Recercat. Dipósit de la Recerca de Catalunya r-FSJD: Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu Fundació Sant Joan de Déu Dipòsit Digital de la UB Universidad de Barcelona BMC Pediatrics, Vol 17, Iss 1, Pp 1-3 (2017) |
| ISSN: | 1471-2431 |
| Popis: | BACKGROUND: Kawasaki disease (KD) is an acute self-limited systemic vasculitis of unknown etiology. Intravenous immunoglobulin (IVIG) is an effective treatment and decreases the risk of cardiac complications to less than 5%. In spite of its effectiveness, some children do not respond to this therapy and still develop coronary aneurysms (CAA). The optimal treatment for IVIG non-responsive patients remains controversial although corticoids have been suggested to be an effective treatment in some patients. For those patients still resistant to IVIG and corticoids, interleukin-1 receptor antagonists (IL-1RA) such anakinra could be an alternative. CASE PRESENTATION: We present a 3 year-old Caucasian patient with KD without cardiac complications but with important resistance to treatment. After becoming resistant to IVIG and corticoids, anakinra proved to be an effective treatment. CONCLUSIONS: To our knowledge, this is the first report of the utility of IL-1RA in refractory KD without coronary impairment. The patient fulfilled the classical criteria for KD and, after becoming resistant to first and second line treatments, anakinra proved to be an effective treatment. Further studies are required to determine if this is an effective treatment option for other cases of resistant Kawasaki disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink